{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Follicular+Thyroid+Cancer&page=2",
    "query": {
      "condition": "Stage II Follicular Thyroid Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Follicular+Thyroid+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:28:35.984Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00104871",
      "title": "Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insular Thyroid Cancer",
        "Recurrent Thyroid Cancer",
        "Stage II Follicular Thyroid Cancer",
        "Stage II Papillary Thyroid Cancer",
        "Stage IV Follicular Thyroid Cancer",
        "Stage IV Papillary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2004-12",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2018-12-19",
      "last_synced_at": "2026-05-21T23:28:35.984Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104871"
    },
    {
      "nct_id": "NCT00095693",
      "title": "Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Thyroid Cancer",
        "Insular Thyroid Cancer",
        "Recurrent Thyroid Cancer",
        "Stage III Follicular Thyroid Cancer",
        "Stage III Papillary Thyroid Cancer",
        "Stage IV Follicular Thyroid Cancer",
        "Stage IV Papillary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "fludeoxyglucose F 18",
          "type": "RADIATION"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "dynamic contrast-enhanced magnetic resonance imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2004-10",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2014-01-16",
      "last_synced_at": "2026-05-21T23:28:35.984Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00095693"
    },
    {
      "nct_id": "NCT00559949",
      "title": "Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Thyroid Gland Carcinoma",
        "Stage I Thyroid Gland Papillary Carcinoma",
        "Stage II Thyroid Gland Papillary Carcinoma",
        "Stage III Thyroid Gland Papillary Carcinoma",
        "Stage IV Thyroid Gland Papillary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2007-12",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-05-21T23:28:35.984Z",
      "location_count": 5,
      "location_summary": "Tampa, Florida • Chicago, Illinois • Chapel Hill, North Carolina + 2 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00559949"
    },
    {
      "nct_id": "NCT00026533",
      "title": "Thalidomide in Treating Patients With Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kenneth Ain",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2001-06",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2017-06-06",
      "last_synced_at": "2026-05-21T23:28:35.984Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026533"
    },
    {
      "nct_id": "NCT00061906",
      "title": "Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2003-01",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2014-02-11",
      "last_synced_at": "2026-05-21T23:28:35.984Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00061906"
    },
    {
      "nct_id": "NCT02973997",
      "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Columnar Cell Variant Thyroid Gland Papillary Carcinoma",
        "Follicular Variant Thyroid Gland Papillary Carcinoma",
        "Metastatic Thyroid Gland Follicular Carcinoma",
        "Metastatic Thyroid Gland Papillary Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Follicular Carcinoma",
        "Recurrent Thyroid Gland Papillary Carcinoma",
        "Stage III Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage III Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage III Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7",
        "Tall Cell Variant Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Hurthle Cell Carcinoma",
        "Unresectable Differentiated Thyroid Gland Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2018-02-07",
      "completion_date": "2023-10-08",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-05-21T23:28:35.984Z",
      "location_count": 7,
      "location_summary": "Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02973997"
    },
    {
      "nct_id": "NCT00729157",
      "title": "Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Thyroid Gland Carcinoma",
        "Stage III Thyroid Gland Follicular Carcinoma",
        "Stage III Thyroid Gland Papillary Carcinoma",
        "Stage IV Thyroid Gland Follicular Carcinoma",
        "Stage IV Thyroid Gland Papillary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Fludeoxyglucose F-18",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ziv-Aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2008-08",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-05-21T23:28:35.984Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00729157"
    },
    {
      "nct_id": "NCT01811212",
      "title": "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Stage I Thyroid Gland Follicular Carcinoma",
        "Stage I Thyroid Gland Papillary Carcinoma",
        "Stage II Thyroid Gland Follicular Carcinoma",
        "Stage II Thyroid Gland Papillary Carcinoma",
        "Stage III Thyroid Gland Follicular Carcinoma",
        "Stage III Thyroid Gland Papillary Carcinoma",
        "Stage IVA Thyroid Gland Follicular Carcinoma",
        "Stage IVA Thyroid Gland Papillary Carcinoma",
        "Stage IVB Thyroid Gland Follicular Carcinoma",
        "Stage IVB Thyroid Gland Papillary Carcinoma",
        "Stage IVC Thyroid Gland Follicular Carcinoma",
        "Stage IVC Thyroid Gland Papillary Carcinoma",
        "Tall Cell Variant Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Oncocytic Follicular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2013-05-08",
      "completion_date": "2017-10-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-03",
      "last_synced_at": "2026-05-21T23:28:35.984Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Jacksonville, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01811212"
    },
    {
      "nct_id": "NCT00098813",
      "title": "Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Thyroid Cancer",
        "Stage IV Follicular Thyroid Cancer",
        "Stage IV Papillary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "romidepsin",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2004-10",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2014-05-28",
      "last_synced_at": "2026-05-21T23:28:35.984Z",
      "location_count": 1,
      "location_summary": "Commack, New York",
      "locations": [
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098813"
    },
    {
      "nct_id": "NCT00381641",
      "title": "Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Thyroid Gland Carcinoma",
        "Stage III Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage III Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7",
        "Thyroid Gland Oncocytic Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2006-08-29",
      "completion_date": "2024-12-10",
      "has_results": true,
      "last_update_posted_date": "2025-03-28",
      "last_synced_at": "2026-05-21T23:28:35.984Z",
      "location_count": 17,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 13 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00381641"
    }
  ]
}